Magenta Therapeutics, Inc.
MGTANASDAQHealthcare
$0.70
$-0.06(-7.74%)
Market Cap$42441024
P/E Ratio—
52W High$1.81
52W Low$0.321
Magenta Therapeutics, Inc. (MGTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MGTA · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 2, 2023EPS Actual
-$0.27
Est. -$0.30 · +10.0%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 2, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
MGTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 1, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 13, 2024 | — | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$0.30 | -$0.27 | +10.0% | — | — | — |
| ▼ Q3 FY2023 | Aug 3, 2023 | $0.19 | $0.05 | -73.7% | — | — | — |
| ▼ Q2 FY2023 | Jun 5, 2023 | $0.41 | -$8.21 | -2102.8% | — | — | — |
| ▼ Q1 FY2023 | Mar 8, 2023 | -$0.27 | -$7.38 | -2633.6% | — | — | — |
| ▼ Q4 FY2022 | Nov 3, 2022 | $0.31 | $0.27 | -12.9% | — | — | — |
| ▼ Q3 FY2022 | Aug 4, 2022 | $0.37 | $0.29 | -21.6% | — | — | — |
Q3 FY2024
Aug 1, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 13, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$0.27
EPS Est.
-$0.30
EPS Surpr.
+10.0%
Revenue
—
Q3 FY2023
Aug 3, 2023Miss
EPS Actual
$0.05
EPS Est.
$0.19
EPS Surpr.
-73.7%
Revenue
—
Q2 FY2023
Jun 5, 2023Miss
EPS Actual
-$8.21
EPS Est.
$0.41
EPS Surpr.
-2102.8%
Revenue
—
Q1 FY2023
Mar 8, 2023Miss
EPS Actual
-$7.38
EPS Est.
-$0.27
EPS Surpr.
-2633.6%
Revenue
—
Q4 FY2022
Nov 3, 2022Miss
EPS Actual
$0.27
EPS Est.
$0.31
EPS Surpr.
-12.9%
Revenue
—
Q3 FY2022
Aug 4, 2022Miss
EPS Actual
$0.29
EPS Est.
$0.37
EPS Surpr.
-21.6%
Revenue
—
No analyst estimates available for MGTA.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 2, 2023 | +10.0% | $0.70 | — | — |
| ▼ Q3 FY2023 | Aug 3, 2023 | -73.7% | $0.81 | $0.83 | +2.84% |
| ▼ Q2 FY2023 | Jun 5, 2023 | -2102.8% | $0.72 | $0.72 | +0.70% |
| ▼ Q1 FY2023 | Mar 8, 2023 | -2633.6% | $0.81 | $0.78 | -4.53% |
| ▼ Q4 FY2022 | Nov 3, 2022 | -12.9% | $1.23 | $1.29 | +4.88% |
| ▼ Q3 FY2022 | Aug 4, 2022 | -21.6% | $1.63 | $1.70 | +4.29% |
| ▲ Q2 FY2022 | May 16, 2022 | +14.7% | $1.14 | $1.10 | -3.51% |
| ▲ Q1 FY2022 | Mar 8, 2022 | +3.1% | $2.55 | $2.73 | +7.06% |
Q4 FY2023—
Report Date
Nov 2, 2023
EPS Beat/Miss
+10.0%
Price Before
$0.70
Price After
—
Q3 FY2023+2.84%
Report Date
Aug 3, 2023
EPS Beat/Miss
-73.7%
Price Before
$0.81
Price After
$0.83
Q2 FY2023+0.70%
Report Date
Jun 5, 2023
EPS Beat/Miss
-2102.8%
Price Before
$0.72
Price After
$0.72
Q1 FY2023-4.53%
Report Date
Mar 8, 2023
EPS Beat/Miss
-2633.6%
Price Before
$0.81
Price After
$0.78
Q4 FY2022+4.88%
Report Date
Nov 3, 2022
EPS Beat/Miss
-12.9%
Price Before
$1.23
Price After
$1.29
Q3 FY2022+4.29%
Report Date
Aug 4, 2022
EPS Beat/Miss
-21.6%
Price Before
$1.63
Price After
$1.70
Q2 FY2022-3.51%
Report Date
May 16, 2022
EPS Beat/Miss
+14.7%
Price Before
$1.14
Price After
$1.10
Q1 FY2022+7.06%
Report Date
Mar 8, 2022
EPS Beat/Miss
+3.1%
Price Before
$2.55
Price After
$2.73
Avg Beat Reaction+1.77%
Avg Miss Reaction+1.64%
Beat Rate3 / 8 quarters
Largest Move+7.06% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MGTA ends December
Magenta Therapeutics, Inc. (MGTA) most recently reported earnings on November 2, 2023 for Q4 FY2023, posting EPS of $-0.27 — beating the analyst consensus of $-0.30 by +10.0%. The next MGTA earnings date is expected around September 1, 2026.
Each quarter, investors track MGTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MGTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MGTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MGTA earnings · 5 questionsMagenta Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MGTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MGTA historically reports after market close (AMC).
MGTA earnings datewhen is MGTA earningsMGTA next earnings datewhen does MGTA report earningsMGTA earnings calendar
▸ Source: FMP · Magenta Therapeutics, Inc. SEC filings · US GAAP · Magenta Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026